Catalog

PD-1/PD-L1 Programmed Death-1/Programmed Death-Ligand 1

Inhibitors

Cat.No.	Name	Information
M9416	Durvalumab	Durvalumab (MEDI 4736) is an humanized anti-PD-L1 monoclonal antibody, it completely blocks the binding of PD-L1 to both PD-1 and CD80, with IC50s of 0.1 and 0.04 nM, respectively.
M8959	PD1-PDL1 inhibitor 1	PD1-PDL1 inhibitor 1 is an inhibitor of the PD-1 /PD-Ll protein/protein interaction with IC50 value of 6 nM.
M6102	Pembrolizumab	Pembrolizumab is a potent, highly selective, fully humanized immunoglobulin (Ig) G4-kappa monoclonal antibody against PD-1 with potential immune checkpoint inhibitory and antineoplastic activities. MW : 146.286 KD.
M6101	Atezolizumab	Atezolizumab is a fully humanized, IgG1 monoclonal antibody that blocks the interaction of PD-L1 with both PD-1 and B7.1, but not the interaction of PD-L2 with PD-1. MW : 145 KD.
M6100	Nivolumab	Nivolumab is a genetically engineered, fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1,PCD-1) with immune checkpoint inhibitory and antineoplastic activities. MW : 143.597 KD.
M5144	BMS202	BMS202 (PD-1/PD-L1 inhibitor 2) is a inhibitor of the PD-1 (Programmed death- 1) /PD-L1 (Programmed death-ligand 1) protein/protein interaction with IC50 value of 18 nM.
M3813	Avelumab (MSB0010718C)	Avelumab is a whole monoclonal antibody of isotype IgG1 that binds to the programmed death-ligand 1 (PD-L1) and therefore inhibits binding to its receptor programmed cell death 1 (PD-1).